Vitamin K prophylaxis is universally recommended for newborns to prevent life-threatening vitamin K deficiency bleeding. Although not listed on routine immunization schedules, vitamin K is frequently given alongside other neonatal preventive measures such as the hepatitis B birth dose and erythromycin ophthalmic ointment. The authors hypothesized that growing hesitancy around vaccines and preventive care could extend to refusal or non-receipt of vitamin K at birth.
This retrospective cohort study used de-identified electronic health record (EHR) data from Truveta with linked mother-child dyads. The study period spanned January 1, 2019 through June 30, 2026. Data were normalized and made available to researchers after expert determination under the HIPAA Privacy Rule; the investigators reported that IRB approval was not required because only de-identified medical records were used.
The analytic sample included live births to mothers aged 15–49 years during the study window. Vitamin K administration was defined by documentation on the birth date or the following day. The authors report counts and percentages of documented receipt versus non-receipt within the cohort of births captured in the Truveta dataset.
Logistic regression models were used to assess sociodemographic predictors of non-receipt of vitamin K prophylaxis, including maternal age, ethnicity, insurance type, and year of delivery. An interrupted time series analysis evaluated changes in the temporal trend after January 2026 to identify potential shifts in the rate of administration coincident with that time point.
Among 1,026,375 infants in the cohort, 995,628 (96.97%) had documented vitamin K administration on the birth date or the following day. The proportion of infants without documented vitamin K increased over the study period. The authors report an average non-receipt rate of 2.1% for 2019–2022, rising to 4.3% in 2025 and 6.1% in 2026, with a peak of 8.10% in June 2026.
Interrupted time series analysis examining the period after January 2026 found no immediate step change in administration rates at that point. However, the odds of vitamin K receipt declined an additional 10% per month after January 2026 (odds ratio [OR] 0.90; 95% confidence interval [CI] 0.88–0.91), indicating an accelerating downward trend in documented administration.
In adjusted analyses, the following characteristics were associated with greater odds of vitamin K non-receipt: older maternal age, non-Hispanic or Latino ethnicity, and Medicaid or unknown insurance. Year of delivery was also associated with higher odds of non-receipt, reflecting the overall temporal increase described above. The source provides these associations but does not present additional numerical effect sizes for each sociodemographic category beyond the OR reported for the post-January 2026 trend.
The authors emphasize that official vitamin K recommendations were not changed by the January vaccine schedule referenced in their interrupted time series analysis. Therefore, they interpret the observed acceleration in non-receipt after January 2026 as potentially reflecting broader impacts on confidence in newborn preventive care rather than a change in clinical guidance. They recommend further research to examine causal mechanisms and parental decision-making that may underlie this trend.
The study used de-identified EHR data available to Truveta subscribers; because the dataset is derived from routine clinical documentation, completeness and accuracy depend on clinical recording practices. The source notes that institutional review board approval was not required given use of de-identified records under applicable regulations. The authors disclose that all are employees of Truveta, Inc. and hold equity in the company. Specific limitations such as potential unmeasured confounding, reasons for missing documentation, or linkage quality between mother and infant are not detailed in the source beyond the statements above.
Documented non-receipt of vitamin K prophylaxis increased across the study period from 2019 through June 2026 and accelerated after January 2026. Sociodemographic factors including older maternal age, non-Hispanic or Latino ethnicity, and Medicaid or unknown insurance were associated with higher odds of non-receipt. The authors call for future studies to investigate causal pathways, parental decision-making, and related clinical outcomes to understand the clinical significance and public health implications of rising non-receipt.
All data used in this study are available to Truveta subscribers and may be accessed at studio.truveta.com. The authors declare that they are employees of Truveta, Inc. and hold equity in the company. The preprint is posted on medRxiv under a CC-BY-NC-ND 4.0 International license. The source reports that all relevant ethical guidelines were followed and that necessary patient/participant consent and protections for de-identified data were in place.